| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 83251 |
Fmoc-Tyr(CH2-Chx)-OH，N-α-(9-芴基甲氧基羰基)-4-环己基甲氧基-L-苯丙氨酸 |
350 |
wyh |
2024-12-23 |
| 83252 |
cas:1337889-01-6，Ald-Ph-amido-PEG11-C2-NH2 |
147 |
zyl |
2024-12-23 |
| 83253 |
长链脂肪酸衍生物MAMA-(CH2)17COOH |
194 |
h |
2024-12-23 |
| 83254 |
cas:1807501-86-5，2,5-dioxopyrrolidin-1-yl 1-(bicyclo[6.1.0]non-4-yn-9-yl)-3-oxo-2,7,10,13,16-pentaoxa-4-azanonadecan-19-oate |
139 |
zyl |
2024-12-23 |
| 83255 |
1059189-65-9，m-PEG4-CH2-aldehyde |
158 |
wyh |
2024-12-23 |
| 83256 |
cas:886209-60-5，perfluorophenyl 2-(cyclooct-2-ynyloxy)acetate |
230 |
zyl |
2024-12-23 |
| 83257 |
DOOCCH2CH2COOD烷基链试剂 |
164 |
h |
2024-12-23 |
| 83258 |
cas:1092654-47-1，Azido-PEG3-CH2CO2-NHS |
147 |
wyh |
2024-12-23 |
| 83259 |
N-芴甲氧羰基-五聚乙二醇-乙酸，Fmoc-NH-PEG5-CH2COOH |
174 |
wyh |
2024-12-23 |
| 83260 |
cas:1232769-29-7，Mal-CO-PEG5-NHS ester |
178 |
zyl |
2024-12-23 |
| 83261 |
氨基-PEG4-丁酸，Amino-PEG4-(CH2)3CO2H |
198 |
wyh |
2024-12-23 |
| 83262 |
cas:1342211-31-7， MC-Val-Ala-OH |
151 |
zyl |
2024-12-23 |
| 83263 |
cas:150244‐18‐1，sulfo-LC-SPDP |
193 |
zyl |
2024-12-23 |
| 83264 |
Azido-PEG3-CH2CO2Me，叠氮-三聚乙二醇-CH2CO2甲基 |
281 |
wyh |
2024-12-23 |
| 83265 |
cas:663598-89-8，1-(4-((5-nitropyridin-2-yl)disulfanyl)butanoyloxy)-2,5-dioxopyrrolidine-3-sulfonic acid |
174 |
zyl |
2024-12-23 |
| 83266 |
99mTc-HYNIC-PEG4-E[PEG4-c（RGDfk）]2(即99mTc-3PRGD2) |
329 |
wyh |
2024-12-23 |
| 83267 |
cas:121115-30-8 SPDP-sulfo 2,5-dioxo-1-(3-(pyridin-2-yldisulfanyl)propanoyloxy)pyrrolidine-3-sulfonic acid |
190 |
zyl |
2024-12-23 |
| 83268 |
MP-PEG8-Val-Ala-PAB-(imp)PBD的组成部分 |
204 |
wyh |
2024-12-23 |
| 83269 |
perfluorophenyl 3-(2-(2-(2-(1,3-dioxoisoindolin-2-yloxy)ethoxy)ethoxy)ethoxy)propanoate |
201 |
zyl |
2024-12-23 |
| 83270 |
MC-Val-Cit-PABC-BF211，抗体药物偶联物(ADCs) |
240 |
wyh |
2024-12-23 |
| 83271 |
2,3,4,5,6-pentafluorophenyl 3-[2-(2-{2-[(4-formylphenyl)formamido]ethoxy}ethoxy)ethoxy]propanoate |
141 |
zyl |
2024-12-23 |
| 83272 |
DOPG:DOPC Liposomes,磷脂酰甘油与磷脂酰胆碱脂质体 |
482 |
axc |
2024-12-23 |
| 83273 |
cas:1353012-00-6，perfluorophenyl 1-azido-3,6,9,12-tetraoxapentadecan-15-oate |
177 |
zyl |
2024-12-23 |
| 83274 |
1V209-PEG23-TA ， 4，7，10-三氧杂-1，13-十三烷二胺和α-甘露糖 |
248 |
wyh |
2024-12-23 |
| 83275 |
cas:943858-70-6，Azidobutyric acid NHS ester |
236 |
zyl |
2024-12-23 |
| 83276 |
DOPG Liposomes,磷脂酰甘油脂质体 |
189 |
axc |
2024-12-23 |
| 83277 |
(64)Cu-NOTA-PEG4-LLP2A的结构组成 |
162 |
wyh |
2024-12-23 |
| 83278 |
99mTc(CO)3-DPA-DBCO-PEG4-CTT-54的显像效果 |
227 |
wyh |
2024-12-23 |
| 83279 |
DOPS:DOPC Liposomes,磷脂酰丝氨酸与磷脂酰胆碱脂质体 |
514 |
axc |
2024-12-23 |
| 83280 |
2,5-dioxopyrrolidin-1-yl 11-oxo-4,7,13-trioxa-10-azahexadec-15-yn-1-oate |
173 |
zyl |
2024-12-23 |
| 83281 |
DOPC Liposomes,二油酰磷脂酰胆碱脂质体 |
245 |
axc |
2024-12-23 |
| 83282 |
DTPA(Gd)-PEG8-(FY)3的结构特点 |
169 |
wyh |
2024-12-23 |
| 83283 |
Fucα1-2Gal-O-(CH2)3-NH-CS-NH-Fluorescein |
166 |
h |
2024-12-23 |
| 83284 |
DSPC Liposomes,二硬脂酰磷脂酰胆碱脂质体 |
309 |
axc |
2024-12-23 |
| 83285 |
GlcNAcβ1-3Galβ1-4Glc-O-(CH2)3-NH-Lipoic |
195 |
h |
2024-12-23 |
| 83286 |
HSPC Liposomes,氢化大豆磷脂酰胆碱脂质体 |
404 |
axc |
2024-12-23 |
| 83287 |
cas:80307-12-6，GMBS，N-(4-马来酰亚胺丁酰基)琥珀酰亚胺 |
233 |
zyl |
2024-12-23 |
| 83288 |
DMPC Liposomes,二肉豆蔻酰磷脂酰胆碱脂质体 |
364 |
axc |
2024-12-23 |
| 83289 |
Galβ1-4GlcNAcβ1-3Gal-O-(CH2)3-NH-DBCO 含DBCO的核心2型丙糖(接头-DBCO A) |
209 |
h |
2024-12-23 |
| 83290 |
DSPC:Chol Liposomes,二硬脂酰磷脂酰胆碱-胆固醇脂质体 |
612 |
axc |
2024-12-23 |
| 83291 |
Galβ1-3GlcNAcβ1-3Gal-O-(CH2)3-NH-CS-NH-Fluorescein |
242 |
h |
2024-12-23 |
| 83292 |
HSPC:Chol Liposomes,磷脂酰丝氨酸-胆固醇脂质体 |
896 |
axc |
2024-12-23 |
| 83293 |
Glcα1-4[Glcα1-4]8Glc-O-(CH2)3-NH-CS-NH-Fluorescein |
282 |
h |
2024-12-23 |
| 83294 |
DMPC:Chol Liposomes,二肉豆蔻酰磷脂酰胆碱-胆固醇脂质体 |
207 |
axc |
2024-12-23 |
| 83295 |
C34-PEG4-Chol ，胆固醇标记LA HIV融合抑制剂 |
192 |
wyh |
2024-12-23 |
齐岳微信公众号
官方微信
库存查询